vs
Side-by-side financial comparison of Piedmont Realty Trust, Inc. (PDM) and Protagonist Therapeutics, Inc (PTGX). Click either name above to swap in a different company.
Protagonist Therapeutics, Inc is the larger business by last-quarter revenue ($170.6M vs $143.3M, roughly 1.2× Piedmont Realty Trust, Inc.). Protagonist Therapeutics, Inc runs the higher net margin — 77.2% vs -31.4%, a 108.6% gap on every dollar of revenue. On growth, Protagonist Therapeutics, Inc posted the faster year-over-year revenue change (184.4% vs 0.4%).
Piedmont Realty Trust, Inc. is a publicly traded real estate investment trust (REIT) that owns, operates, and invests in high-quality office properties primarily located in high-growth metropolitan areas across the United States. It serves corporate tenants across multiple industry sectors including technology, professional services, and healthcare, and pursues stable long-term returns for stakeholders via strategic property management and portfolio optimization.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel peptide-based targeted therapies for unmet medical needs, primarily covering gastrointestinal disorders, inflammatory diseases and rare disease indications. Its lead product candidates target inflammatory bowel disease and other chronic immune-related conditions, with operations spanning global R&D and partnership collaborations.
PDM vs PTGX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $143.3M | $170.6M |
| Net Profit | $-45.0M | $131.7M |
| Gross Margin | — | — |
| Operating Margin | — | 74.3% |
| Net Margin | -31.4% | 77.2% |
| Revenue YoY | 0.4% | 184.4% |
| Net Profit YoY | -27.9% | 381.7% |
| EPS (diluted) | $-0.10 | $2.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $143.3M | — | ||
| Q4 25 | $142.9M | — | ||
| Q3 25 | $139.2M | — | ||
| Q2 25 | $140.3M | — | ||
| Q1 25 | $142.7M | — | ||
| Q4 24 | $143.2M | $170.6M | ||
| Q3 24 | $139.3M | — | ||
| Q2 24 | $143.3M | — |
| Q1 26 | $-45.0M | — | ||
| Q4 25 | $-43.2M | — | ||
| Q3 25 | $-13.5M | — | ||
| Q2 25 | $-16.8M | — | ||
| Q1 25 | $-10.1M | — | ||
| Q4 24 | $-30.0M | $131.7M | ||
| Q3 24 | $-11.5M | — | ||
| Q2 24 | $-9.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 74.3% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | -31.4% | — | ||
| Q4 25 | -30.3% | — | ||
| Q3 25 | -9.7% | — | ||
| Q2 25 | -12.0% | — | ||
| Q1 25 | -7.1% | — | ||
| Q4 24 | -20.9% | 77.2% | ||
| Q3 24 | -8.3% | — | ||
| Q2 24 | -6.8% | — |
| Q1 26 | $-0.10 | — | ||
| Q4 25 | $-0.34 | — | ||
| Q3 25 | $-0.11 | — | ||
| Q2 25 | $-0.14 | — | ||
| Q1 25 | $-0.08 | — | ||
| Q4 24 | $-0.25 | $2.01 | ||
| Q3 24 | $-0.09 | — | ||
| Q2 24 | $-0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.3M | $418.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.5B | $675.3M |
| Total Assets | $4.0B | $744.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $2.3M | — | ||
| Q4 25 | $731.0K | — | ||
| Q3 25 | $3.0M | — | ||
| Q2 25 | $3.3M | — | ||
| Q1 25 | $2.9M | — | ||
| Q4 24 | $109.6M | $418.9M | ||
| Q3 24 | $133.6M | — | ||
| Q2 24 | $138.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.2B | — | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | — | ||
| Q4 24 | $2.2B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.2B | — |
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.6B | — | ||
| Q4 24 | $1.6B | $675.3M | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | $1.7B | — |
| Q1 26 | $4.0B | — | ||
| Q4 25 | $4.0B | — | ||
| Q3 25 | $4.0B | — | ||
| Q2 25 | $4.0B | — | ||
| Q1 25 | $4.0B | — | ||
| Q4 24 | $4.1B | $744.7M | ||
| Q3 24 | $4.1B | — | ||
| Q2 24 | $4.2B | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.49× | — | ||
| Q3 25 | 1.43× | — | ||
| Q2 25 | 1.41× | — | ||
| Q1 25 | 1.40× | — | ||
| Q4 24 | 1.40× | — | ||
| Q3 24 | 1.36× | — | ||
| Q2 24 | 1.34× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $184.2M |
| Free Cash FlowOCF − Capex | — | $182.8M |
| FCF MarginFCF / Revenue | — | 107.1% |
| Capex IntensityCapex / Revenue | 110.3% | 0.8% |
| Cash ConversionOCF / Net Profit | — | 1.40× |
| TTM Free Cash FlowTrailing 4 quarters | — | $101.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.6M | — | ||
| Q3 25 | $35.8M | — | ||
| Q2 25 | $50.1M | — | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | $198.1M | $184.2M | ||
| Q3 24 | $42.9M | — | ||
| Q2 24 | $66.8M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $182.8M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 107.1% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 110.3% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.8% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.40× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
